During the past decade, Scott and White Cancer Institute conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 7 clinical trials were completed, i.e. on average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Scott and White Cancer Institute" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "University of South Florida" with 2 trials sponsored, "American College of Radiology Imaging Network" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Egetis Therapeutics" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Scott and White Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "Solasia Pharma K.K." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Scott and White Cancer Institute" are "Breast Cancer" (4 trials), "Colorectal Cancer" (2 trials), "Colorectal Neoplasms" (2 trials), "B-cell Non-Hodgkin Lymphoma" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Scott and White Cancer Institute" in a lesser frequency.

Most popular intervention types in "Scott and White Cancer Institute" are "Drug" (7 trials), "Procedure" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "5-fluorouracil" (1 trials), "Aromatase Inhibitor" (1 trials), "Calmangafodipir (2 µmol/kg)" (1 trials) and "Calmangafodipir (5 µmol/kg)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Scott and White Cancer Institute" are 9 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Scott and White Cancer Institute". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Scott and White Cancer Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Scott and White Cancer Institute, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".